RHYTHM PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RHYTHM PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $0 | Mar 8, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $130.13M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $77.43M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $23.64M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.15M | Feb 29, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($196.54M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($260.60M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($184.68M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($181.12M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($69.61M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($134.00M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | ($32.96M) | Mar 2, 2020 |
| FY2019 | Sep 30, 2019 | ($36.00M) | Mar 2, 2020 |
| FY2019 | Jun 30, 2019 | ($42.80M) | Mar 2, 2020 |
| FY2019 | Mar 31, 2019 | ($28.97M) | Mar 2, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($192.02M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($265.50M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($184.36M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($179.16M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($170.06M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($136.58M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($146.00M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($78.42M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($32.41M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($25.91M) | Mar 8, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.34M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $237.96M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $134.95M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $108.63M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $104.13M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $90.45M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $109.45M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $50.34M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $22.89M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $19.59M | Mar 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.94M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $144.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $117.53M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $92.03M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $68.49M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $46.13M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $36.55M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $28.08M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $9.52M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $6.31M | Mar 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($115.68M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($113.88M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($136.16M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($173.43M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($146.00M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($121.98M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($122.75M) | Mar 1, 2021 |
| FY2020 | Dec 31, 2018 | ($62.06M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($29.46M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($23.22M) | Mar 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $953.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $47.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $281.0K | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $434.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $214.0K | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $3.39M | Mar 1, 2021 |
| FY2020 | Dec 31, 2018 | $722.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $133.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.06M | Mar 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $392.27M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $332.75M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $382.48M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $329.52M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $187.07M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $308.52M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $260.21M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $151.74M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $12.34M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.17M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $227.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $162.99M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $118.22M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $45.37M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $20.55M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $27.50M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $13.95M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $6.95M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $5.04M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $139.07M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $21.73M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $169.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $264.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $284.15M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $166.53M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $281.02M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $246.26M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $144.79M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | ($32.70M) | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.35B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.16B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($894.74M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($710.06M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($528.94M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($459.33M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($325.33M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($184.60M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($110.25M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($76.54M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $89.14M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $60.08M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $127.68M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $59.25M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $100.85M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $62.29M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $49.54M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $34.24M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $6.54M | Mar 12, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (3) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 67.21M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 62.39M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 59.43M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 56.61M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 50.28M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 44.24M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 44.00M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 34.41M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 27.28M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 10.20M | Mar 12, 2018 |